Tolerx, Inc.

Tolerx Completes Enrollment in DEFEND-1, A Phase 3 Type 1 Diabetes Study With Otelixizumab

Cambridge, Massachusetts (ots/PRNewswire) - Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes. The DEFEND-1 (Durable Response Therapy Evaluation For Early ...